PointofLaw.com
 Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  
   
 
   

 

 

McDarby: Gilmartin to testify



Peter Lattman reports in the WSJ law blog, via Heather Won Tesoriero, that the plaintiffs' lawyers in the McDarby trial plan to call Ray Gilmartin, former Merck CEO (1994-2005), to the stand for the punitive damages portion of the trial. Gilmartin has thusfar not testified in any Vioxx trial.

The plaintiffs' strategy is to paint Merck under Gilmartin as a rogue company that "put profits before patient safety." To receive punitive damages under New Jersey law, the plaintiffs will have to convince the jury that Merck knowingly misled the FDA about Vioxx's safety profile.

As Tesoriero explains, punitive damages in New Jersey are limited to the greater of $350,000 or five times compensatory damages, so the extra damage for Merck in this case will be cabined. But how Gilmartin performs on the stand could dramatically affect expectations for future trials.

 

 


Isaac Gorodetski
Project Manager,
Center for Legal Policy at the
Manhattan Institute
igorodetski@manhattan-institute.org

Katherine Lazarski
Press Officer,
Manhattan Institute
klazarski@manhattan-institute.org

 

Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.